CLL
Feature
CLL drug in limited supply outside U.S.
Patients outside the United States will be able to access the drug only through compassionate use programs.
Conference Coverage
Venetoclax/rituximab boosts PFS in relapsed/refractory CLL
ATLANTA – "I believe that venetoclax/rituximab should be considered as a suitable standard therapeutic option in patients with relapsed CLL."
Conference Coverage
VIDEO: Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
ATLANTA – Dr. John Seymour discussed results from a study comparing bendamustine/rituximab with venetoclax/rituximab in relapsed/refractory CLL...
Conference Coverage
CLL drug combinations induce MRD negativity
ATLANTA – The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies...
Conference Coverage
CLARITY: Ibrutinib/venetoclax combo results look promising for relapsed/refractory CLL
ATLANTA – Ibrutinib/venetoclax is well tolerated and shows promise for relapsed/refractory CLL, according to early CLARITY feasibility trial...
Conference Coverage
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
Conference Coverage
Studies need to address best follow-on therapy to ibrutinib in CLL
There was no clear standard treatment approach for patients with CLL who discontinued ibrutinib or for whom ibrutinib did not work, in a...
Conference Coverage
Idelalisib efficacy against CLL tarnished by toxicity
Only one in five patients on idelalisib in registration trials remained on the drug after 2 years.
Conference Coverage
Deep remission or long-term control? Choice is key in early CLL
Sequencing therapy in chronic lymphocytic leukemia depends on patient characteristics, prior therapy, frailty, and mutations.
Conference Coverage
M13-982 trial in del(17p) CLL: High, durable response rates to venetoclax
Venetoclax monotherapy is well tolerated and associated with high and durable objective response rates in patients with del(17p) CLL, according to...
From the Journals
Ibrutinib and bleeding complications in Mohs surgery
Temporary discontinuation of ibrutinib might reduce bleeding risks.